CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) To Contact Brower Piven Before The Lead Plaintiff Deadline
STEVENSON, Md., Oct. 10, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) (“Alnylam” or the “Company”) securities during the period between February 15, 2018 and September 12, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until November 26, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Alnylam securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection.
According to the complaint, following a September 12, 2018 announcement by an analyst that a review document released by the U.S. Food and Drug Administration’s (“FDA”) Center for Drug Evaluation and Research highlighted greater risk with respect to certain trials of Alnylam’s ONPATTRO (patisiran) lipid complex injection, a limited market opportunity in TTRcardiomyopathy, a potential platform safety risk, and concerns over cardiac deaths in patients treated with ONPATTRO, the value of Alnylam shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Alnylam securities purchased on or after February 15, 2018 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at email@example.com or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. PivenBrower Piven, A Professional Corporation1925 Old Valley RoadStevenson, Maryland 21153Telephone: 410-415-6616 firstname.lastname@example.org